Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma

Abstract

Tumors of the upper gastrointestinal tract are increasing in incidence; yet, approaches to the treatment of advanced gastric and/or gastroesophageal junction cancer vary widely, with no internationally agreed first-line regimens. Recent clinical trials have shown that second-line treatment is now possible for selected patients with advanced disease, and current data suggest that the combination of ramucirumab plus paclitaxel may become a standard of care in the second-line setting for metastatic gastric cancer. Several prognostic factors have been identified for overall survival in the second-line setting; this emphasizes the need for careful sequencing of all treatments to ensure that individual patients receive optimum care. This article reviews published data on the treatment of advanced gastric cancer, with a particular emphasis on second-line chemotherapy, and suggests treatment sequences based on current understanding.

The possibility of effective second-line treatment for patients with advanced gastric cancer increases the need for careful decision-making in first-line therapy. Treatment sequencing should be based on current evidence and should aim to improve the chances of benefit from second-line treatment.

http://ift.tt/2emy7B4